Rosalind Franklin University Helix 51 Company Saros Therapeutics Receives Second $2 Million Award to Advance Cancer Immunotherapy

Phase 2Positive

AI Analysis

Summary

Saros Therapeutics, a company in Rosalind Franklin University's Helix 51 biomedical incubator, received its second $2 million National Cancer Institute Phase II award to advance cancer immunotherapy research.

Clinical Trial Data

Phase

Phase II

Outcome Details

Second NCI Phase II award received

Importance:5/10

Sentiment:

0.60

cancer immunotherapyNCI fundingHelix 51 incubatorgrant award

Related Companies

$NHPAP

Read the original article

Published by PR Newswire Pharma on October 2, 2026 4:00 PM

Read Original